Printer Friendly

AMERICAN BIOGENETIC SCIENCES RECEIVES U.S. PATENT FOR BLOOD CLOT DETECTION ANTIBODY

 AMERICAN BIOGENETIC SCIENCES RECEIVERS U.S. PATENT
 FOR BLOOD CLOT DETECTION ANTIBODY
 NOTRE DAME, Ind., June 1 /PRNewswire/ -- American Biogenetic Sciences, Inc. (ABS) (NASDAQ: MABXA) announced today that it has received United States Patent No. 5,120,834 covering its blood clot detection antibody.
 Michael D. Ezckowitz, M.D., Ph.D., professor of medicine at Yale University and chief of cardiology at the West Haven VA Medical Center says that this antibody is specific to fibrin and is potentially applicable, not only for the detection of deep vein thrombosis, but for locating clots in the heart and lung which if successful, would be a medical breakthrough. Using a proprietary labelling technology, the antibody is tagged to technetium, an imaging agent and can be used to pinpoint the location of a clot within fifteen minutes after injection in animals. An Investigational New Drug (IND) application has been filed on March 9, 1992, with the Food and Drug Administration (FDA) for approval to begin the first human trials at the West Haven VA Medical Center with this proprietary antibody. Present methods for locating blood clots involve invasive, uncomfortable and lengthy procedures for the patient.
 According to William R. Bell, professor of medicine, Radiology and nuclear medicine at the Johns Hopkin's University School of Medicine, Baltimore, "the success of these human trials will eliminate the need for invasive angiography to demonstrate blood clots inside the body, angiography involves the use of a large number of personnel and expensive equipment. In addition, it puts the patient at risk."
 Because of its specificity and affinity, this antibody is also being developed to deliver clot dissolving drugs such as tPA and Streptokinase directly to the site of a clot thereby reducing the cost of treatment and risk of hemorrhage to the patient.
 This fibrin specific antibody is part of the ABS unique and proprietary monoclonal antibody for detecting and treating cardiovascular disease. The FDA has already approved a diagnostic it utilizing another proprietary ABS antibody for measuring fibrinogen in a patient's blood. Fibrinogen, according to a number of respected medical studies, including the Framingham Study, is a more important factor than cholesterol in determining the risk of an impending heart attack or stroke.
 Blood clots leading to heart attacks and strokes are the leading cause of death in the developed world. The U.S. annual incidence is over two million cases of which 500,000 are estimated to die annually as a result.
 American Biogenetic Sciences, Inc. is a biopharmaceutical company which conducts research at the University of Notre Dame, Ind., Trinity College, Dublin, Ireland and University College Galway, Ireland, to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease, the early detection of Alzheimer's disease and breast cancer. These antibodies are produced from the company's proprietary virtually antigen-free mouse colony.
 -0- 6/1/92
 /CONTACT: Fran Giambanco, senior vice president of American Biogenetic Sciences, 516-789-2600, or Phil Fried of Dilenschneider Group, 212-922-0900, for American Biogenetic Sciences/
 (MABXA) CO: American Biogenetic Sciences, Inc. ST: Indiana IN: MTC SU:


TS-OS -- NY013 -- 5551 06/01/92 09:38 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 1, 1992
Words:515
Previous Article:WESTINGHOUSE, ROLLS-ROYCE FORM ALLIANCE FOR POWER GENERATION
Next Article:ASM INTERNATIONAL ANNOUNCES OPERATING IMPROVEMENT FOR 1991; OUTLOOK FOR 1992
Topics:


Related Articles
ONCOGENE SCIENCE ISSUED TWO PATENTS FOR RAS ONCOGENE
ONCOGENE SCIENCE ISSUED PATENT FOR RAS ONCOGENE
SOCIETE GENERALE SECURITIES CORPORATION & HEALTHCARE CAPITAL GROUP APPOINTED AMERICAN BIOGENETIC SCIENCES FINANCIAL ADVISORS
SOCIETE GENERALE SECURITIES AND HEALTHCARE CAPITAL GROUP SPONSORING AMERICAN BIOGENETIC SCIENCES PRESENTATION TO MEET NEW COMPANY PRESIDENT
AMERICAN BIOGENETIC SCIENCES, INC. AND MEDEVA PLC TO DEVELOP NEW HEPATITIS A VACCINE
AMERICAN BIOGENETIC SCIENCES REPORTS AGREEMENT WITH NEW ENGLAND DEACONESS HOSPITAL AND HARVARD MEDICAL SCHOOL FOR CLINICAL EVALUATION OF 'SOLFIB,'...
AMERICAN BIOGENETIC SCIENCES OBTAINS U.S. PATENT FOR METHOD OF DIAGNOSING ALZHEIMER'S DISEASE
American Biogenetic Sciences, Inc. Announces Intent To Build Diagnostic Business Through Acquisition
Tiny Nasdaq Company Has Breakthrough Technology of Extreme Importance In Prevention, Diagnosis And Treatment Of Cancer, Alzheimer's, Strokes And...
American Biogenetic obtains patent for the treatment of malignant and benign tumors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters